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Abstract: Calcium pterins have been shown to be significant immunotherapeutic agents in 
models of breast cancer, hepatitis B, and tuberculosis (Bacillus Calmette-Guérin mycobacteria). 
These compunds modulate the immuno-enzyme indoleamine 2,3-dioxygenase (IDO) and the 
blood levels of several identified inflammatory cytokines. Recent research into the pathology of 
diabetes implicates inflammatory factors in the progression of the disease, leading the authors to 
study its possible control by one of the calcium pterins, dipterinyl calcium pentahydrate (DCP).
The investigators tested DCP as a novel therapeutic for type 2 diabetes. Female C57BL/6 J 
mice with diet-induced obesity were fed a high-fat diet and were administered DCP in 0.4% 
carboxymethylcellulose for 21 days. Blood glucose was followed during the dosing period, 
and an oral glucose tolerance test (OGTT) was carried out on day 21. Measurements of plasma 
indoleamine 2,3-dioxygenase metabolites (tryptophan and kynurenine) and certain cytokines and 
chemokines were also taken. DCP 7 mg/kg/day reduced OGTT area under the curve (OGTT/
AUC) by 50% (P , 0.05). A significant multivariate   regression (P = 0.013; R2 = 0.571) of OGTT/
AUC was derived from DCP dosage and plasma Trp. Elevated plasma Trp concentration, likely 
from heterogeneity in diet and/or indoleamine 2,3-dioxygenase activity, was found to correlate 
with higher OGTT/AUC diabetic measures,   possibly via inhibition of histamine degradation. 
In conclusion, an optimum dose of DCP 7 mg/kg/day significantly improved the OGTT diabetic 
state in these female diet-induced obese mice.
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Introduction
Dipterinyl calcium pentahydrate (DCP) is a new molecular entity, the structure of 
which is based upon the endogenous substance pterin, and it works through a novel 
  immunomodulatory mechanism. DCP has shown antitumor efficacy in mouse   models of 
breast cancer1 and antiviral activity in transgenic mice with hepatitis B virus,2 as well as 
antimycobacterial activity in an in vitro model of tuberculosis (Bacille   Calmette-Guérin).3 
Preclinical studies have also shown that DCP works through a broad immunomodulatory 
mechanism involving a key immunoinhibitory enzyme,   indoleamine 2,3-dioxygenase 
(IDO), which DCP appears to modulate to a “  homeostatic” level. DCP inhibits IDO in 
some systems1–3 and promotes it in others,3 including the diet-induced obesity (DIO) 
model, as reported here. DCP also increases the plasma cytokines interleukin (IL)-12 
and IL-4,4 and chemokine granulocyte-macrophage colony-stimulating factor,2 while 
decreasing IL-64 and monocyte chemoattractant protein-1.2 DCP potentiated monocyte 
antimycobacterial activity by induction of the CC chemokine macrophage inflammatory 
protein-1 beta, and inducible nitric oxide synthase 2.3
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Emerging literature5,6 suggests that inflammation, as 
evaluated by high   inflammatory cytokine levels and other 
inflammatory markers, may represent a basic cause and 
consequence of obesity, type 2 diabetes, and comorbidities. 
Modulation of the levels of anti-inflammatory and proinflam-
matory cytokines may be an important strategy of therapeutic 
intervention in the treatment of type 2 diabetes and metabolic 
disease. The authors hypothesized that oral administration of 
DCP can improve glucose tolerance by normalizing the levels 
of proinflammatory cytokines, which are elevated in obesity 
and type 2 diabetes. Effects on glucose tolerance and other 
measures in vivo were determined in mice fed a high-fat diet 
to induce obesity and insulin resistance. DCP was found to 
significantly improve oral glucose tolerance, as determined 
by 2-hour area under curve (AUC) comparisons.
Methods
Twenty-four female diet-induced obese (DIO) C57BL/6J 
mice7 (000664, B6; The Jackson Laboratory–West, 
  Sacramento, CA) were used because they were presumed 
to have higher levels of IDO than males, based upon an 
earlier study.2 The mice were fed ad libitum a high-fat 
diet (D12492i, 60 kcal % fat; Research Diets Inc, New 
Brunswick, NJ) from 6 to 18 weeks of age. For 21 days 
afterwards, the test article, DCP in 0.4% carboxymethylcel-
lulose, was administered daily by oral gavage at 0, 7, 21, 
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Figure 1 (A) fasting blood glucose levels and (B) body weights of female diet-induced obese (DIO) C57BL/6 J mice during the 21-day dipterinyl calcium pentahydrate (DCP) 
dosing period. The mice were divided into four treatment groups of DCP 0, 7, 21, or 63 mg/kg/day.
Abbreviation: SEM, standard error of the mean.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
44
Nikoulina et alDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2012:5
or 63 mg/kg/day to four groups of six mice each. During 
the DCP gavaging period three mice were lost because of 
gavaging trauma: one control and two from the 63 mg/kg/
day group. Two of the plasma samples collected after DCP 
dosing were inadvertently not labeled and were therefore 
excluded from the analyses: one from the 21 mg/kg/day 
group and one from the 63 mg/kg/day.
Blood glucose measurements were taken from fasted 
animals twice weekly as follows:
1.  Animals were fasted for 6 hours prior to blood 
collection.
2.  Blood (approximately 10–20 µL) was collected via tail 
snip. The scab was removed for subsequent blood sam-
pling, until 2 mm of the tail tip was removed. Additional 
bleeds were then done via tail pricks (ie, sticking the vein 
or artery with a needle) from all animals, beginning just 
prior to group assignment. Blood glucose was measured 
using the OneTouch® Ultra®2 blood glucose monitoring 
system (LifeScan, Inc, Milpitas, CA).
3.  During the 21-day DCP dosing period, blood was collected 
2 hours post dose on days 1, 3, 5, 9, 10, 13, 17, and 21.
4.  On day 21 after DCP administration, an oral glucose 
tolerance test (OGTT) was carried out measuring pre-
challenge blood glucose, and then at 30, 60, 90, and 
120 minutes post challenge with glucose 2 g/kg.
Plasma samples were collected by cardiac puncture on day 
21 after DCP administration. The plasma IDO metabolites, 
tryptophan (Trp) and kynurenine (Kyn), were measured by 
high-performance liquid chromatography.8 EMD Millipore (St 
Charles, MO) measured the following cytokines and chemok-
ines using a 96-well plate assay (Mouse Cytokine/Chemokine 
Magnetic Bead Panel Kit, #MCYTOMAG-70 K; Millipore 
Corporation): granulocyte-macrophage colony-stimulating 
factor, interferon gamma, IL-1 alpha, IL-1 beta, IL-4, IL-6, 
IL-10, IL-12(p40), IL-12(p70), IL-13, monocyte chemoat-
tractant protein-1, RANTES (regulated on activation, normal 
T cell expressed and secreted), and tumor necrosis factor 
alpha. Reported precisions for the overnight protocol for these 
cytokines and chemokines are intra-assay percent coefficient of 
variation #4.9% and inter-assay percent coefficient of varia-
tion #12.4%. Plasma insulin and other glucose metabolism 
regulator levels were not determined for this pilot study.
Table 1 One-way analyses of variance of oral glucose (glu) tolerance test area under the curve (OGTT/AUC); plasma indoleamine 
2,3-dioxygenase metabolites tryptophan (Trp), kynurenine (Kyn), and calculated Kyn/Trp ratio; and certain cytokines/chemokines
Mean ± SEM  
(N = 19)
DCP 0 mg/kg/day  
(n = 5)
DCP 7 mg/kg/day  
(n = 6)
DCP 21 mg/kg/day  
(n = 5)
DCP 63 mg/kg/day   
(n = 3)
OGTT/AUC mg · minute/dL* 5218 ± 905 2632† ± 517 4085 ± 600 5868 ± 831
0-minute glu (mg/dL) 170 ± 15 172 ± 20 183 ± 11 162 ± 17
30-minute glu (mg/dL)**** 233 ± 11 207 ± 11 277† ± 19 312††† ± 7.8
60-minute glu (mg/dL) 200 ± 18 201 ± 17 211 ± 15 211 ± 7.5
90-minute glu (mg/dL)** 241 ± 15 178†† ± 15 163†† ± 7.7 192† ± 18
120-minute glu (mg/dL) 162 ± 13 159 ± 12 162 ± 6.3 183 ± 15
Trp (µM) 110 ± 14 110 ± 9.0 119 ± 12 122 ± 5.0
Kyn (µM)** 0.90 ± 0.14 0.96 ± 0.10 1.00 ± 0.19 1.84†† ± 0.25
Kyn/Trp (µM/mM)* 8.34 ± 1.0 8.92 ± 0.87 8.52 ± 1.3 15.13† ± 2.0
GM-CSF (pg/mL) ,160 ,160 ,160 192 ± 32
IFNγ (pg/mL) ,6.4 ,6.4 ,6.4 15.7 ± 9.3
IL-1α (pg/mL) 467 ± 258 (4) 496 ± 170 329 ± 225 348 ± 197
IL-1β (pg/mL) 34.7 ± 2.7 (4) ,32.0 41.6 ± 8.5 36.7 ± 4.7
IL-4 (pg/mL) 7.76 ± 1.4 ,6.4 8.34 ± 1.9 ,6.4
IL-6 (pg/mL) 59.2 ± 8.8 (4) 24.7 ± 9.6 43.2 ± 8.2 (4) 56.2 ± 36.6
IL-10 (pg/mL) ,32.0 49.0 ± 17.0 32.8 ± 0.76 ,32.0
IL-12(p40) (pg/mL) 32.5 ± 0.52 (4) ,32.0 ,32.0 (4) ,32.0
IL-12(p70) (pg/mL) 69.0 ± 31.5 37.8 ± 5.8 123.6 ± 80.5 72.9 ± 23.8
IL-13 (pg/mL) 197 ± 23.1 ,160 ,160 765 ± 604.7
MCP-1 (pg/mL) 70.8 ± 26.1 46.0 ± 14.0 49.6 ± 13.3 60.3 ± 22.2
RANTES (pg/mL) 36.6 ± 3.0 (4) 46.6 ± 13.0 33.1 ± 1.1 (3) 49.5 ± 17.5
TNFα (pg/mL) 12.0 ± 5.3 8.0 ± 1.6 10.2 ± 2.4 9.5 ± 3.1
Notes: *P , 0.05, **P , 0.01, ***P , 0.005, ****P = 0.001, for all DCP dosages tested; †P , 0.05, ††P , 0.01, †††P , 0.005, for contrast tests versus 0 mg/kg/day. When actual 
cell numbers are different these are given in parentheses.
Abbreviations:  DCP,  dipterinyl  calcium  pentahydrate;  GM-CSF,  granulocyte-macrophage  colony-stimulating  factor;  IL,  interleukin;  IL-1α,  interleukin-1  alpha;  IL-1β, 
interleukin-1 beta; IFNγ, interferon gamma; MCP-1, monocyte chemoattractant protein-1; RANTES, regulated on activation, normal T cell expressed and secreted; SEM, 
standard error of the mean; TNFα, tumor necrosis factor alpha.
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Standard and repeated measures analysis of variance 
(ANOVA) and stepwise regression of the data were carried 
out using SPSS statistical software (GradPack, v 15.0, and v 
19 for Windows; IBM Corporation, Armonk, NY). The test 
of homogeneity of variances was performed to determine the 
appropriate contrast tests to be used in the one-way ANOVAs.   
A P-value ,0.05 was used to establish   statistical significance.
Results
During the 21-day DCP dosing period there was no signifi-
cant difference in blood glucose levels (Figure 1A) or body 
weights (Figure 1B) among the four treatment groups of 
DCP 0, 7, 21, or 63 mg/kg/day, as determined by repeated 
measures ANOVA. The mice appeared to be hyperglycemic 
on the high-fat diet and not strikingly obese.
OGTT/AUC, plasma IDO metabolite, and cytokine/
chemokine measures using ANOVAs are given in Table 1, 
showing a significant 50% OGTT/AUC decrease for the mice 
treated with DCP 7 mg/kg/day (P , 0.05).
Four variables were identified by stepwise regression to 
yield the following OGTT/AUC linear regression (P = 0.013; 
R2 = 0.571; see Table 2):
OGTT/AUC = 0.009 DCP3 + 31.178 DCP2
  – 574.513 DCP+ 29.828 Trp  
  + 1935.382,  (1)
where DCP is the DCP dosage (mg/kg/day) and Trp is the 
plasma Trp concentration (µM). From this equation it can 
be predicted that lowered plasma Trp levels are expected to 
improve (ie, decrease) OGTT/AUC measures.
The DCP dose corresponding to the minimum (least 
diabetic) OGTT/AUC values can be determined by setting 
the first derivative of this equation equal to 0:
0   = d(OGTT/AUC) ÷ d(DCP)  
= 0.027 DCP2 + 62.356 DCP – 574.513,  (2)
which can be solved for DCP by using the quadratic 
formula:
DCP =
--
=
-
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 DCP 9.19 mg/kg/day
  (3)
This DCP dosage calculated from the regression equa-
tion corresponds very well with the experimentally derived 
value of 7 mg/kg/day from Table 1 for the antidiabetic dosage 
  giving the minimum OGTT/AUC.
Discussion
From the values shown in Table 1 for Trp, Kyn, and the 
calculated Kyn/Trp ratio, it appears that IDO activity is not 
involved with the antidiabetic OGTT/AUC minimum at DCP 
7 mg/kg/day. Interestingly, the plasma IL-6 pattern shown in 
Table 1, although nonsignificant, resembles the significant 
(P , 0.05) OGTT/ AUC pattern, in that the lowest values 
for IL-6 and OGTT/AUC both correspond to a DCP dose of 
7 mg/kg/day. Previous resear chers have called for investiga-
tion into the role of IL-6 in diabetes types 1 and 26 and its 
role in the immune system generally in type 2 diabetes.5
Of particular interest is the finding that plasma Trp 
enters into the significant (P = 0.013)   multivariate   regression 
  predicting the OGTT/AUC response (Table 2). US Food 
and Drug Administration researchers9 have determined 
that elevated Trp levels can lead to increased   formation 
of   formate and indolyl metabolites, several of which 
inhibit the degradation of histamine, potentially leading 
to   eosinophilia-myalgia syndrome and diabetes.10 In this 
regard, 98% of surveyed   eosinophilia-myalgia syndrome 
patients from the United States reported   having used 
L-Trp-containing products prior to the onset of i  llness 
at a median dosage of 1500 mg/day.11 This human dose 
(1500 mg/70 kg = 21 mg/kg) corresponds to a mouse dosage 
of 264 mg/kg, based upon allometric scaling. The estimated 
corresponding mouse plasma/tissue level increase,
264 mg/kg × (Trp mmoL/Trp 204 mg) × (kg/0.7 L) 
= Trp 1.85 mM,
Table 2 Multivariate linear regression of oral glucose tolerance 
test area under the curve (OGTT/AUC) Coefficientsa
Model Unstandardized  
coefficients
Standardized  
coefficients
t-statisticP-value
B SE Beta
(Constant) 1935.382 1717.742 NA 1.127 0.279
DCP3 0.009 0.003 17.143 2.650 0.019
DCP2 31.178 11.113 23.797 2.806 0.014
DCP -574.513 190.252 -6.604 -3.020 0.009
Trp 29.828 14.533 0.369 2.052 0.059
Notes:  aDependent  variable  is  OGTT/AUC.  Trp,  Kyn,  Kyn/Trp,  granulocyte-
macrophage colony-stimulating factor, interferon gamma, IL-1 alpha, IL-1 beta, IL-4, 
IL-6,  IL-10,  IL-12(p40),  IL-12(p70),  IL-13,  monocyte  chemoattractant  protein-1, 
RANTES, and tumor necrosis factor alpha were tested by stepwise regression as 
predictors of OGTT/AUC. The selected variables were DCP3, DCP2, DCP, and Trp 
(µM), where DCP is dosage (mg/kg/day); P = 0.013, R2 = 0.571 for the regression 
OGTT/AUC = 0.009 DCP3 + 31.178 DCP2 – 574.513 DCP + 29.828 Trp + 1935.382.
Abbreviations: DCP, dipterinyl calcium pentahydrate; Kyn, kynurenine; NA, not 
applicable; RANTES, regulated on activation, normal T cell expressed and secreted; 
SE, standard error; Trp, tryptophan.
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or, if not allometrically scaling,
21 mg/kg × (Trp mmoL/Trp 204mg) × (kg/0.7 L) 
      = Trp 0.15 mM,  (4)
which in either case substantially increases the DIO mouse 
plasma Trp levels beyond those shown in Table 1.
Conclusion
In conclusion, the authors find:
1.  DCP significantly (P , 0.05) improves oral glucose 
tolerance at 7 mg/kg/day in female DIO mice.
2.  A significant (P = 0.013) multiple regression, in terms of 
DCP3, DCP2, and DCP dosages, and plasma Trp levels, 
can be constructed, which explains 57% of the OGTT/
AUC variance in this measure of glucose tolerance in the 
DIO mice.
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